sfleong1
2021-12-26
Like n comment
Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术公司 TC BioPharm 将交易规模降低 40%，并在 3000 万美元美国 IPO 之前增加认股权证</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698553634,"tweetId":"698553634","gmtCreate":1640476244231,"gmtModify":1640476244915,"author":{"id":3583570345500843,"idStr":"3583570345500843","authorId":3583570345500843,"authorIdStr":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":66,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like n comment</p></body></html>","htmlText":"<html><head></head><body><p>Like n comment</p></body></html>","text":"Like n comment","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698553634","repostId":1130212885,"repostType":4,"repost":{"id":"1130212885","kind":"news","pubTimestamp":1640397757,"share":"https://www.laohunote.com/m/news/1130212885?lang=zh_CN&edition=full","pubTime":"2021-12-25 10:02","market":"us","language":"en","title":"Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术公司 TC BioPharm 将交易规模降低 40%，并在 3000 万美元美国 IPO 之前增加认股权证</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130212885","media":"Renaissance Capital","summary":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,","content":"<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.</p><p><blockquote>TC BioPharm Holdings 是一家开发同种异体 gamma-delta T 细胞疗法的苏格兰 2 期生物技术公司，周四降低了其即将进行的 IPO 的拟议交易规模。</blockquote></p><p> The Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.<i>Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.</i></p><p><blockquote>这家总部位于英国霍利敦的公司目前计划以 8 美元的价格发行 380 万股美国存托凭证，筹集 3000 万美元。该公司还发行 380 万份认股权证，以 8 美元的价格购买 ADS，每份行使价为 10 美元。该公司此前曾申请以 7 至 9 美元的价格发行 630 万股股票。按照修订后的价格，TC BioPharm Holdings 筹集的收益将比之前预期少 40%。<i>由于该公司现在发行认股权证，TC BioPharm 不再有资格追踪，并将被排除在 Renaissance Capital 的统计数据之外。</i></blockquote></p><p> TC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.</p><p><blockquote>TC BioPharm (TCB) 专注于基于其专有的同种异体 γ-δ T 细胞 (GD-T) 平台开发新型免疫疗法。该公司的 Omnimmune 项目预计将在2021年第四季度进入治疗急性髓性白血病 (AML) 的 2 期至关键（3 期）试验。该公司计划在 2022 年上半年向 FDA 提出申请后，在美国对 AML 进行类似的试验。TCB 还在开发用于治疗 COVID-19 的 GD-T 疗法，预计将在2021年第四季度开始试验，以及用于治疗实体癌的转基因 CAR-T 疗法。</blockquote></p><p> TC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.</p><p><blockquote>TC BioPharm Holdings成立于2013年，截至2021年9月30日的12个月收入为300万美元。它计划在纳斯达克上市，股票代码为 TCBP。EF Hutton 是该交易的唯一账簿管理人。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术公司 TC BioPharm 将交易规模降低 40%，并在 3000 万美元美国 IPO 之前增加认股权证</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术公司 TC BioPharm 将交易规模降低 40%，并在 3000 万美元美国 IPO 之前增加认股权证</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-12-25 10:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.</p><p><blockquote>TC BioPharm Holdings 是一家开发同种异体 gamma-delta T 细胞疗法的苏格兰 2 期生物技术公司，周四降低了其即将进行的 IPO 的拟议交易规模。</blockquote></p><p> The Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.<i>Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.</i></p><p><blockquote>这家总部位于英国霍利敦的公司目前计划以 8 美元的价格发行 380 万股美国存托凭证，筹集 3000 万美元。该公司还发行 380 万份认股权证，以 8 美元的价格购买 ADS，每份行使价为 10 美元。该公司此前曾申请以 7 至 9 美元的价格发行 630 万股股票。按照修订后的价格，TC BioPharm Holdings 筹集的收益将比之前预期少 40%。<i>由于该公司现在发行认股权证，TC BioPharm 不再有资格追踪，并将被排除在 Renaissance Capital 的统计数据之外。</i></blockquote></p><p> TC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.</p><p><blockquote>TC BioPharm (TCB) 专注于基于其专有的同种异体 γ-δ T 细胞 (GD-T) 平台开发新型免疫疗法。该公司的 Omnimmune 项目预计将在2021年第四季度进入治疗急性髓性白血病 (AML) 的 2 期至关键（3 期）试验。该公司计划在 2022 年上半年向 FDA 提出申请后，在美国对 AML 进行类似的试验。TCB 还在开发用于治疗 COVID-19 的 GD-T 疗法，预计将在2021年第四季度开始试验，以及用于治疗实体癌的转基因 CAR-T 疗法。</blockquote></p><p> TC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.</p><p><blockquote>TC BioPharm Holdings成立于2013年，截至2021年9月30日的12个月收入为300万美元。它计划在纳斯达克上市，股票代码为 TCBP。EF Hutton 是该交易的唯一账簿管理人。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130212885","content_text":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.\nTC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.\nTC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1188,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698553634"}
精彩评论